EPRX Stock Summary and Trading Ideas (Eupraxia Pharmaceuticals | NASDAQ:EPRX)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Eupraxia Pharmaceuticals trades on the NASDAQ stock market under the symbol EPRX.

As of August 31, 2026, EPRX stock price declined to $6.58 with 24,899 million shares trading.

EPRX has a beta of 1.13, meaning it tends to be more sensitive to market movements. EPRX has a correlation of 0.09 to the broad based SPY ETF.

EPRX has a market cap of $434.76 million. This is considered a Small Cap stock.

EPRX has outperformed the market in the last year with a return of +24.9%, while the SPY ETF gained +19.3%. However, in the most recent history, EPRX shares have underperformed the stock market with its stock returning -10.8% in the last 3 month period and -2.1% for the last 2 week period, while SPY has returned +1.8% and -1.3%, respectively.

EPRX support price is $6.36 and resistance is $6.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EPRX shares will trade within this expected range on the day.